Dashboard
1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 2.90%
- Poor long term growth as Operating profit has grown by an annual rate 25.03% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -227.81
2
With ROE of 22.71%, it has a Very Expensive valuation with a 8.33 Price to Book Value
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
29.78%
0%
29.78%
6 Months
55.46%
0%
55.46%
1 Year
34.68%
0%
34.68%
2 Years
89.84%
0%
89.84%
3 Years
105.71%
0%
105.71%
4 Years
211.28%
0%
211.28%
5 Years
236.53%
0%
236.53%
argenx SE for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
124.98%
EBIT Growth (5y)
25.03%
EBIT to Interest (avg)
-227.81
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.61
Sales to Capital Employed (avg)
0.25
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.01%
ROCE (avg)
0
ROE (avg)
2.90%
Valuation key factors
Factor
Value
P/E Ratio
37
Industry P/E
Price to Book Value
8.33
EV to EBIT
110.92
EV to EBITDA
104.98
EV to Capital Employed
21.54
EV to Sales
14.24
PEG Ratio
0.05
Dividend Yield
NA
ROCE (Latest)
19.42%
ROE (Latest)
22.71%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,024.80
1,134.30
78.51%
Operating Profit (PBDIT) excl Other Income
-42.90
-314.20
86.35%
Interest
2.30
0.80
187.50%
Exceptional Items
20.90
13.30
57.14%
Consolidate Net Profit
770.10
-272.90
382.19%
Operating Profit Margin (Excl OI)
-29.20%
-367.80%
33.86%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 78.51% vs 190.25% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 382.19% vs 59.58% in Dec 2023
About argenx SE 
argenx SE
Pharmaceuticals & Biotechnology
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.






